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Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
is an effective therapy for various malignant and non-malignant
diseases. Many patients have now been followed for two or
three decades posttransplant and are presumed to be cured.
With the tremendous advances achieved in terms of supportive
care, it is reasonable to expect outcomes to improve steadily
and consequently increasing numbers of transplant survivors
will be facing life after the initial transplant experience.
Although long-term allo-HSCT survivors generally enjoy good
health, for many others, cure or control of the underlying
disease is not accompanied by full restoration of health. The
burden of long-term morbidity borne by allo-HSCT survivors is
substantial, and long-term follow-up of patients who received
allo-HSCT is now widely recommended. Immediate survival is
no longer the sole concern after allo-HSCT. The goals should
also include complete recovery of the overall health status with
normal physical and psychological functioning. Long-term side
effects after allo-HSCT include non-malignant organ or tissue
dysfunction, changes in quality of life, infections related to
abnormal immune reconstitution and secondary cancers. Many
of these can be attributed to the deleterious effects of chronic
graft-versus-host disease. The aims of this review are to
provide an update on the recent research evidence in the ﬁeld.
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Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
is an effective therapy for various malignant and non-malignant
diseases. Many patients have now been followed for two or
three decades post-transplant and are presumed to be cured. At
present, the allo-HSCT transplant activity is steadily increasing
worldwide. This increase is mainly driven by the use of the
so-called reduced intensity conditioning (RIC) regimens, and
because of access to alternative stem cell sources from human
leukocyte antigen-matched or mismatched unrelated adult
donors and from cord blood. A recent analysis, published from
the Seattle Group, found a substantial reduction in the hazard of
death over the past decade when comparing the period from
1993–1997 to 2003–2007. Improved outcomes appear to be
related to reductions in organ damage, infection and severe
acute graft-versus-host disease (GVHD).
1 With the tremendous
advances achieved in terms of supportive care, it is reasonable
to expect outcomes to improve substantially, and consequently
increasing numbers of transplant survivors will be facing life
after the initial transplant experience. Although long-term allo-
HSCT survivors generally enjoy good health, for many others
cure or control of the underlying disease is not accompanied by
full restoration of health.
2 When looking to all-cause mortality in
a cohort of almost 1500 patients who survived 2 or more years
after allo-HSCT, mortality rates remain twice as high as that of
the general population among 15-year survivors of allo-HSCT,
and that the survivors face challenges affecting their health and
well-being. Relapse of primary disease (29%) and chronic
GVHD (cGVHD; 22%) were the leading causes of premature
death.
3 Moreover, in patients who have survived for at least 5
years after allo-HSCT without recurrence of the original disease,
life expectancy is still not fully restored. Mortality rates
remained four- to ninefold higher than those expected in the
general population for at least 30 years after transplantation,
providing an estimated 30% lower life expectancy, regardless of
current age. In rank order, the leading causes of excess deaths
were second malignancies and recurrent disease, followed by
infections, cGVHD, respiratory diseases and cardiovascular
diseases.
4 The burden of long-term morbidity borne by allo-
HSCT survivors is substantial, and long-term follow-up of
patients who received allo-HSCT is now widely recommended.
Allo-HSCT survivors were twice as likely as siblings to develop a
chronic condition, and 3.5 times to develop severe/life-
threatening conditions, whereas allo-HSCT survivors with
cGVHD were 4.7 times as likely to develop severe/life-
threatening conditions.
5 In terms of health-care utilization by
long-term survivors after allo-HSCT, more than 95% of the
patients reported medical contact and the prevalence of general
physical examination increased with time, highlighting the
need for increased awareness of long-term side effects after
allo-HSCT.
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At present, immediate survival is no longer the sole concern
after allo-HSCT, as many patients can survive the acute
complications of the procedure and remain free of their original
disease for several years. As a matter of fact, the primary aim of
allo-HSCT is the cure from the primary disease. However, the
goals should also include complete recovery of the health status
with normal physical and psychological functioning but also
normal family and social integration with good subjective
well-being. Long-term side effects after allo-HSCT include non-
malignant organ or tissue dysfunction, changes in quality of
life, infections related to abnormal immune reconstitution and
secondary cancers. Many of these can be attributed to the
deleterious effects of cGVHD. Almost all organs and tissues can Received 6 February 2011; accepted 24 February 2011
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Nevertheless, one should also take into account the common
diseases or other comorbidities that the patient might have had
before transplantation. Also, one should consider the issues of
physiological aging and the impact of lifestyle and environment.
Among the transplant community, it is common to deﬁne all
events occurring beyond 3 months after allo-HSCT as late
complications, and separate them into delayed (from 3 months
to 2 years), late (2–10 years) and very late events (410 years).
7
Figure 1 summarizes the different steps that may be considered
as risk factors for long-term side effects after allo-HSCT. These
risk factors can be related to the patient and disease features or
to the transplant technique itself, including the choice of
conditioning regimen, the choice of the graft source and the
occurrence of long-term cGVHD. Despite an ever-growing
knowledge of the natural history of the side effects of allogeneic
bone marrow transplantation, long-term complications and the
features of cGVHD symptoms are heterogeneous in nature, time
of onset, duration and severity. The latter parameters may
depend on the intensity of the conditioning regimen and
immunosuppressive therapies used. The aims of this review
are not to provide a comprehensive list of the different late
complications occurring after allo-HSCT, but rather an update
on the recent research evidence in the ﬁeld. Recommended
screening and preventive practices were published elsewhere
and will not be discussed here.
8 Also, speciﬁc complications
encountered in the pediatric allo-HSCT population, will not be
addressed.
Role of the conditioning regimen
Intensity of the conditioning regimen, especially the use of
full-dose myeloablative total body irradiation (TBI) is likely to
have a major role in the onset of diverse late complications after
allo-HSCT. Several studies have demonstrated an impact of TBI
on cataract formation with an incidence of o20% in the no-TBI
group versus more than 80% in the single-dose TBI group.
9,10
Spermatogenesis provides another example of the deleterious
impact of high-dose TBI, with 85% of the patients receiving TBI
developing azoospermia versus 51% in the no-TBI group.
11 The
incidence of diabetes and hypertension is also signiﬁcantly
increased after allo-HSCT as compared with patient receiving
autologous transplantation or to their siblings. Besides, the use
of radiation therapy appears to be deleterious especially when it
comes to diabetes.
12 As non-myeloablative or RIC regimens are
being increasingly used in the allogeneic setting, one might
question whether the use of RIC will reduce long-term toxicity
after allo-HSCT ? At present, it is well established that RIC can
reduce short-term acute toxicity. However, it has been proven
that the probability of cGVHD is not reduced after RIC because
RIC regimens are mainly used in older patients, in more
advanced diseases with peripheral blood stem cells being the
main graft source.
13–15 In one study assessing chronic kidney
disease in patients that had received RIC versus myeloablative
regimens, there were no signiﬁcant differences in term of renal
complications.
16
Role of the stem cell source and chronic GVHD
The graft source has a major role in long-term side effects,
especially cGVHD. A large meta-analysis that included more
than 1100 patients from nine international randomized trials,
demonstrated a signiﬁcantly higher incidence of extensive
cGVHD when using granulocyte colony-stimulating factor-
mobilized peripheral blood stem cells versus bone marrow.
On the other hand, the incidence and severity of cGVHD is
likely lower after unrelated cord blood transplantation.
17
Chronic GVHD, and its different target organs (Table 1), is
one of the most serious consequence of allo-HSCT, involving
many physical, human, emotional, societal, ﬁnancial and
intellectual resources for the patients and caregivers. Indeed,
active cGVHD has a signiﬁcant impact on many aspects of the
overall health status. In multivariable analyses, subjects with
active cGVHD were more likely to report adverse general
health, mental health, functional impairments, activity limita-
tion and pain than were those with no history of cGVHD.
However, health status did not differ between those with
resolved cGVHD and those who never had cGVHD. Also, the
percentage of chronic GVHD patients with poor general health
status will remain very high at any time after transplantation.
18
Avascular necrosis is one example demonstrating that cGVHD
and its corollary of long-term immunosuppressive therapy are
signiﬁcant risk factors for this complication.
19 The lung is
another important target for cGVHD with different complica-
tions being described thus far. The non-infectious complications
can be divided into the bronchiolitis obliterans syndrome, the
bronchiolitis obliterans-organizing pneumonia and the idio-
pathic pneumonia syndrome.
20 The incidence of pulmonary
non-infectious complications in patients surviving more than 3
months after allo-HSCT transplant is around 10% at 2 years and
the outcome of patients with cGVHD who develop pulmonary
complications is signiﬁcantly worse than cGVHD patients
without pulmonary complications.
21 Bronchiolitis obliterans
syndrome is usually considered as a severe pulmonary manifes-
tation affecting the small airways. Its incidence can range from
2 to 14% and the overall survival is around 13% at 5 years. The
clinical presentation is often insidious, although some patients
may have dry cough, progressive dyspnea or wheezing, without
3
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Figure 1 Long-term side effects after allo-SCT: major risk factors.
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Blood Cancer Journalfever. The diagnosis of bronchiolitis obliterans syndrome is
b a s e do na ne x p i r a t o r yﬂ o wo75% of predicted in addition to
speciﬁc features on high-resolution computed tomography
scan and absence of infection in the respiratory tract.
22,23 An
increasing body of data could show a strong association between
bronchiolitis obliterans syndrome and pulmonary cGVHD.
24
Table 1 Signs and symptoms of chronic GVHD (reproduced from Filipovich et al.
24)
Organ or site Diagnostic (sufﬁcient to
establish the diagnosis of
chronic GVHD)
Distinctive (seen in chronic
GVHD, but insufﬁcient alone
to establish a diagnosis of
chronic GVHD)
Other features
a Common (seen with both
acute and chronic GVHD)
Skin Poikiloderma
Lichen planus-like features
Sclerotic features
Morphea-like features
Lichen sclerous-like features
Depigmentation Sweat impairment
Ichthyosis
Keratosis pilaris
Hypopigmentation
Hyperpigmentation
Erythema
Maculopapular rash
Pruritus
Nails Dystrophy
Longitudinal ridging, splitting,
or brittle features
Onycholysis
Pterygium unguis
Nail loss (usually symmetric;
affects most nails)
b
Scalp and
body hair
New onset of scarring or
nonscarring scalp alopecia
(after recovery from
chemoradiotherapy)
Scaling, papulosquamous lesions
Thinning scalp hair, typically
patchy, coarse, or dull (not
explained by endocrine or
other causes)
Premature gray hair
Mouth Lichen-type features
Hyperkaratotic plaques
Restriction of mouth opening
from sclerosis
Xerostomia
Mucocele
Mucosal atrophy
Pseudomembranes
b
Ulcers
b
Gingivitis
Mucositis
Erythema
Pain
Eyes New-onset dry, gritty, or
painful eyes
c
Cicatricial conjunctivitis
Keratoconjunctivitis sicca
c
Conﬂuent areas of punctuate
keratopathy
Photophobia
Periorbital
Hyperpigmentation
Blepharitis (erythema of
the eyelids with edema)
Genitalia Lichen planus-like features
Vaginal scarring or stenosis
Erosions
b
Fissures
b
Ulcers
b
GI tract Esophageal web
Strictures or stenosis in the
upper to mid third of the
esophagus
b
Exocrine
pancreatic insufﬁciency
Anorexia
Nausea
Vomiting
Diarrhea
Weight loss
Failure to thrive
(infants and children)
Liver Total bilirubin, alkaline
phosphatases 42
upper limit of normal
b
ALT or AST42upper
limit of normal
b
Lung Bronchiolitis obliterans
diagnosed with lung biopsy
Bronchiolitis obliterans diagnosed
with PFTs and radiology
c
BOOP
Muscles,
fascia, joints
Fascilitis
Joint stiffness or contractures
secondary to sclerosis
Myositis or polymyositis
c Edema
Muscle cramps
Arthralgia or arthritis
Hematopoietic
and immune
Thrombocytopenia
Eosinophilia
Lymphopenia
Hypo or
hypergammaglobulinemia
Autoantibodies (AIHA and ITP)
Other Pericardial or pleural effusions
Ascites
Peripheral neuropathy
Nephrotic syndrome
Myasthenia gravis
Cardiac conduction
abnormality or cardiomyopathy
Abbreviations: AIHA, autoimmune hemolytic anemia; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BOOP, bronchiolitis
obliterans-organizing pneumonia; GVHD, graft-versus-host disease; ITP, idiopathic thrombocytopenic purpura; PFTs, pulmonary function tests.
aCan be acknowledged as part of the chronic GVHD symptomatology if the diagnosis is conﬁrmed.
bIn all cases, infection, drug effects, malignancy, or other causes must be excluded.
cDiagnosis of chronic GVHD requires biopsy or radiology conﬁrmation (or Schirmer test for eyes).
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Blood Cancer JournalIn contrast to pulmonary complications, cardiac and vascular
complications usually occur ‘very late’ after allo-HSCT with a
relatively low magnitude of risk during the ﬁrst decade. Indeed,
after 20 years of follow-up, the incidence of arterial events might
be as high as 22%.
25,26 In addition to the allo-HSCT treatment
itself, the usual cardiovascular risk factors such as smoking,
hypertension, diabetes or obesity were shown to be signiﬁcant
factors for an arterial event after allo-HSCT.
25 From the
pathophysiological standpoint, data published in 2002 sug-
gested that host endothelial cells are a target of alloreactive
donor cytotoxic T cells, and there is an extensive loss of
microvessels in the skin of patients with cGVHD, which may
lead to tissue ﬁbrosis, the hallmark lesion of cGVHD.
27
Renal complications are also frequent after allo-HSCT with an
incidence around 23% after a median time of 2.5 years after
transplantation. Older age, hypertension, poor kidney function
before transplantation, but also acute and cGVHD with the use
of calcineurin inhibitors were shown to be risk factors for
chronic kidney disease. The effect of TBI is still controversial.
28–30
Late secondary malignancies after allo-HSCT
Different categories of secondary malignancies can occur after
allo-HSCT, including post-transplant lymphoproliferative dis-
orders, late relapse of the primary disease, donor-type secondary
leukemia/other malignancy and de novo solid tumors. As part of
this Review, we will focus on secondary solid tumors. TBI and
the chemotherapeutic drugs used before allo-HSCT as part of the
conditioning regimen can induce new secondary malignancies
after allo-HSCT. This is attributed to the mutagenic risk of
irradiation and chemotherapy, the genetic predisposition of the
patient to develop cancer, prolonged immunosuppression, and
in elderly patients, to age-related risk.
One of the ﬁrst largest reports, including more than 1000
patients transplanted before December 1985, could show that
the incidence of secondary malignancies is around 3.5% at 10
years and 12.8% at 15 years, which is 3.8-fold higher than that
of an age-matched control population.
31 This study was recently
updated. This update showed that the incidence of secondary
malignancies continued to increase with longer follow-up time
compared with age-matched control population.
32 A more
recent very large analysis including 28874 patients who
received allo-HSCT, showed that solid cancers occurred twice
more frequently than expected in the general population and
this risk reached threefold among patients followed for 15 years
or more. Of note, allo-HSCT survivors irradiated at young ages
had increased risks of solid cancers.
33 Indeed, the risk of
secondary solid cancer may vary depending on the type of
conditioning regimen. In a study including acute and chronic
myeloid leukemia patients receiving high-dose Busulfan and
cyclophosphamide conditioning, the cumulative incidence of
solid cancers at 10 years was 1.2% for acute myeloid leukemia
and 2.4% for chronic myeloid leukemia, which was 1.4 times
higher in comparison with general population incidence rates.
Signiﬁcantly elevated risks were observed for tumors of the oral
cavity, esophagus, lung, soft tissue and brain. Chronic GVHD
was an independent risk factor for all solid cancers, and
especially for cancers of the oral cavity.
34 The picture may also
be different when it comes to some speciﬁc cancers such as
thyroid cancer in which younger age was found to be the
strongest risk factor of secondary thyroid cancer.
35 A joint
EBMT/Seattle study showed that the cumulative incidence of
breast cancer is around 5% at 20 years and the median time to
breast cancer diagnosis is around 12.5 years. Cumulative
incidence was higher among survivors who received TBI than
those who did not receive TBI. In multivariable analysis,
increased risk was associated with longer time since transplan-
tation, use of TBI and younger age at transplantation.
36
Conclusion
Allo-HSCT has the potential to cure a signiﬁcant proportion of
patients with otherwise fatal diseases. However, allo-HSCT
recipients are exposed to long-term complications and side
effects. All of these late complications present a great diversity in
respect to frequencies, time of onset, risk factors, prevention
strategies, treatment approaches and outcomes. In many
patients, long-term survivorship is not accompanied by full
restoration of health. The long-term side effects are usually a
multifactorial and complex process, and the natural history of
such late effects will likely change in the future because the
transplant techniques have been changing signiﬁcantly over the
last three decades. Chronic GVHD remains the most challen-
ging risk factor. A preventable death with a functioning
hematopoietic allograft is not a marker of success. Patients
can have a major role through engagement in health-main-
tenance behaviors.
The long-term goal is maintenance of health and to ensure the
best possible quality of life. Establishment of a close partnership
between the transplant centre, the organ-speciﬁc specialities
and local primary careproviders to provide life-long counseling
and prevention therapy is a key factor for the long-term success
of any transplant program.
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